FunPep
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing functional peptides for skin ulcers and antibody-inducing vaccines, with a Phase III candidate showing angiogenesis and antimicrobial activity.
DermatologyImmunologyInfectious Disease
Technology Platform
Functional peptide design and synthesis platform creating modified peptides with enhanced stability and specific biological activities, including antibody-inducing peptides that stimulate B-cell immune responses.
Opportunities
Potential to address significant unmet need in skin ulcer treatment with SR-0379's dual mechanism of action, and opportunity to disrupt antibody drug market with cost-effective antibody-inducing peptide technology.
Risk Factors
Clinical development risk for Phase III candidate SR-0379, competition in peptide therapeutics space, and unproven technology for antibody-inducing peptides requiring further validation.
Competitive Landscape
Competes with other peptide therapeutic companies and traditional wound care products; differentiation through multifunctional peptides with combined angiogenic/antimicrobial activity and innovative antibody-inducing approach.